About tg therapeutics inc. - TGTX
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
TGTX At a Glance
TG Therapeutics, Inc.
3020 Carrington Mill Boulevard
Morrisville, North Carolina 27560
| Phone | 1-212-554-4484 | Revenue | 233.66M | |
| Industry | Pharmaceuticals: Major | Net Income | 12.67M | |
| Sector | Health Technology | 2023 Sales Growth | 8,290.018% | |
| Fiscal Year-end | 12 / 2024 | Employees | 264 | |
| View SEC Filings |
TGTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 200.234 |
| Price to Sales Ratio | 10.856 |
| Price to Book Ratio | 16.114 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 115.398 |
| Enterprise Value to Sales | 10.399 |
| Total Debt to Enterprise Value | 0.046 |
TGTX Efficiency
| Revenue/Employee | 885,083.333 |
| Income Per Employee | 48,000.00 |
| Receivables Turnover | 4.573 |
| Total Asset Turnover | 0.893 |
TGTX Liquidity
| Current Ratio | 5.919 |
| Quick Ratio | 5.177 |
| Cash Ratio | 4.049 |
TGTX Profitability
| Gross Margin | 93.771 |
| Operating Margin | 8.83 |
| Pretax Margin | 5.59 |
| Net Margin | 5.423 |
| Return on Assets | 4.844 |
| Return on Equity | 11.568 |
| Return on Total Capital | 4.671 |
| Return on Invested Capital | 6.183 |
TGTX Capital Structure
| Total Debt to Total Equity | 69.03 |
| Total Debt to Total Capital | 40.839 |
| Total Debt to Total Assets | 33.616 |
| Long-Term Debt to Equity | 68.129 |
| Long-Term Debt to Total Capital | 40.306 |